Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprocitentan in Resistant Hypertension
NCT03541174Phase 3Completed
- Sponsor
- Idorsia
- Start
- Jun 2018
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial of aprocitentan in resistant hypertension (RH), sponsored by Idorsia. Primary endpoint: Change From Baseline to Week 4 of Double-blind Treatment in Mean Trough Sitting Systolic Blood Pressure. Started Jun 2018; status: completed.
02
Drugs
aprocitentan
03
Conditions
resistant hypertension (RH)
Beyond the preview
Go deeper on NCT03541174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03541174.